ClinicalTrials.gg
RecruitingNCT04068155Updated Jun 16, 2026

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors

An interventional study of DaRT- Diffusing Alpha-emitters Radiation Therapy in Skin Cancer, Cutaneous Tumor and Cutaneous Metastasis, sponsored by Alpha Tau Medical LTD.. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Alpha Tau Medical LTD. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Skin Neoplasms by Alpha Tau Medical LTD. — 5 open to participants now, 7 under way, none of them phase 3. Skin Neoplasms · Alpha Tau Medical LTD..

Planned enrollment
2nd of 11
80 · median 30
Started
2022
with 1 other
No phase
11 of 11
5 open now
Registered
5th of 11
by date

Among the 11 studies in Skin Neoplasms by Alpha Tau Medical LTD., this one is the 2nd largest by planned enrollment, is one of 2 that started in 2022, is one of 11 with no phase, and was the 5th registered.

Skin Neoplasms

606 studies on the registry are indexed under Skin Neoplasms; 127 are open to participants now.

Browse Skin Neoplasms studies →

Open to participants now

5 of the 11 studies in Skin Neoplasms by Alpha Tau Medical LTD. are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 105 Skin Neoplasms studies recruiting now, 85 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Skin Neoplasms by Alpha Tau Medical LTD., or all of them as a file.
02

Study summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors

Read the detailed description

This will be a prospective, open label, single arm, multi- center study, assessing the safety and effectiveness of diffusing alpha emitters radiation therapy (DaRT) delivered through radioactive seeds inserted into the tumor.

This approach combines the advantages of local intratumoral irradiation of the tumor, as used in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that will be introduced in quantities considerably lower than radiation therapy already used in patients.

Cutaneous lesions with histopathological confirmation of malignancy will be treated using DaRT seeds.

Reduction in tumor size 9-11 weeks following DaRT insertion will be assessed. Safety will be assessed by the frequency, severity and causality of all Adverse Events (AE).

03

Conditions studied

  • Skin Cancer
  • Cutaneous Tumor
  • Cutaneous Metastasis

Keywords

  • Squamous Cell Carcinoma
  • Basal Cell Carcinoma
  • Skin Cancer
  • Skin Metastasis
  • Superficial Sarcoma
  • Alpha Radiation
  • Cutaneous Lesion
  • Brachytherapy
  • Radiotherapy
  • Lentigo maligna melanoma
  • Carcinosarcom
  • scalp cancer
  • Lip cancer
  • Eyelid cancer
  • SCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with histopathological confirmation of newly diagnosed (Cohort A) or locally recurrent (Cohort B) malignant cutaneous lesions of the following histopathologies:

    • SCC
    • BCC
    • Lentigo maligna melanoma (Dubreuilh melanoma)
    • Carcinosarcoma
  • Acceptable tumor locations include the following:

    • Skin (facial, scalp, extremities, torso)
    • Lips
    • Eyelids
  • Subjects with a tumor size ≤ 7 centimeters in the longest diameter.
  • Target lesion technically amenable for full tumor coverage with the Alpha DaRT seeds.
  • according to v1.1.
  • Subjects over 18 years old.
  • Subjects' Performance Status Scale is \< 2.
  • Subjects' is more than 6 months.
  • count ≥100,000/mm3.
  • of prothrombin time ≤1.8.
  • Women of (WOCBP) will have evidence of negative pregnancy test.
  • Subjects are willing to sign an form

Exclusion criteria

Exclusion Criteria:

  • Subject has a tumor with histology of one of the following:

    • Keratoacanthoma
    • Merkel cell carcinoma
    • Sarcoma other than carcinosarcoma
  • disease (according to the TNM staging system - M1 patients are excluded)
  • Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled diseases, vasculitis, etc.).
  • Patients undergoing systemic therapy excepting intermittent, brief use of systemic .
  • Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
  • High probability of protocol non-compliance (in opinion of investigator).
  • Subjects not willing to sign an .
  • Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    DaRT Seeds Intratumoral Diffusing alpha-emitters

    An intratumoral insertion of securely fixed seeds loaded with Radium-224. The seeds release by recoil short-lived alpha-emitting atoms into the tumor.

    Device: DaRT- Diffusing Alpha-emitters Radiation Therapy

Interventions

  • DeviceDaRT- Diffusing Alpha-emitters Radiation Therapy

    Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles

06

What researchers measure

Primary outcomes

  1. The objective response rate to DaRT treatment

    Assessment of tumor response rate using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)

    Time frame: up to 9-11 weeks

Secondary outcomes

  1. Tumor volume

    Assessment of the reduction in tumor volume based on imaging tests

    Time frame: up to 9-11 weeks

  2. DaRT seeds placement

    Assessment of the DaRT seed placement by localization of the DaRT seed in the tumor using CT imaging

    Time frame: Day of DaRT insertion procedure

  3. Change in quality of life as assessed by the Skindex-16 questionnaire

    Assessment of patient reported health-related Quality of Life (QoL) outcomes using the Skindex-16 questionnaire

    Time frame: up to 9-11 weeks

  4. Disease-Free Survival (DFS) rate

    Assessment of Disease-Free Survival

    Time frame: up to 24 months

  5. Change in quality of life as assessed by the Skin Cancer Index (SCI) questionnaire

    Assessment of patient reported health-related Quality of Life (QoL) outcomes using the Skin Cancer Index (SCI) questionnaire.

    Time frame: up to 9-11 weeks

Other outcomes

  1. Adverse Events

    Assessment of the frequency, severity and causality of adverse events related and not related to the DaRT treatment. Adverse events will be assessed and graded according to Common Terminology and Criteria for adverse events (CTCAE) version 5.0.

    Time frame: up to 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Jan 2027, 57 months after the start.

Of 116 interventional studies with no phase under Skin Neoplasms, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 66. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2019
First posted
Aug 28, 2019
StartActual
Apr 1, 2022
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04068155
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Apr 1, 2022
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Liron Dimnik
Contact
LironD@alphatau.com
+972-2-373-7000
Amnon Gat
Contact
Amnong@alphatau.com
Dr Pascal POMMIER
principal investigator · Centre Leon Berard
Pr Jean Michel HANNOUN LEVI
principal investigator · Antoine Lacassagne Cancer Center
Dr Camille VERRY
principal investigator · University Hospital, Grenoble

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion